medisourceasia.com

Industry News


Home

About 
medisourceasia

Magazine
Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info

Contact

 

Medical Devices Industry To Grow Beyond $50 Bn: CII-BCG Report

The Indian medical technology sector has the potential to touch $50 billion by 2025 if it continues to grow at 10-12 per cent annually. Globally, the medical technology market is expected to be $600 billion+ by 2025. India can capture 10 per cent of that share by 2025 if provided with adequate support and policy guidance, according to a CII and Boston Consulting Group (BCG) study.

Based on the findings of CII-BCG -Vision Document – 2025 which was unveiled recently in the Capital, it was concluded that the medical technology sector remains highly under–penetrated contributing 7 to 8 per cent of the healthcare spends as compared to pharmaceuticals at 18 per cent.

‘Vision Document – 2025’ prepared by CII and BCG on the medical technology sector also pinpointed that outdated and irrelevant laws like Drugs & Cosmetics Act pose major regulatory hurdles to the medical technology industry. Vision Document 2025 was unveiled by Union Health Secretary Lov Verma and Dr K Vijay Raghavan, secretary, Department of Biotechnology, on the occasion of CII-BCG MedTech event held in New Delhi recently.

Speaking on the sidelines of the 7th Medical Technology Conference following the unveiling ceremony, Amitabh Kant, secretary, Department of Industrial Policy & Promotion (DIPP), Government of India said, “Indian medical technology industry can touch more than $50 billion in the next decade if emphasis is given on local manufacturing with funding and incentives from industry and government.

As per the Vision Document, setting up the right manufacturing capabilities could spur an additional $20 billion manufacturing opportunity for the Indian medical technology space in addition to a $30 billion domestic market opportunity available today. “Therefore it is essential that the sector exploits the cost advantage it wants to compete with China for the global market,” adds Kant.

Lov Verma, Union Health Secretary, said, “The medical technology sector should also look at CSR initiatives at promoting sanitation like building toilets in schools”. While, Dr K Vijay Raghavan, secretary, Department of Biotechnology, Ministry of Science & Technology said that local innovation has to be promoted if the sector has to realise its true potential and that Government will have to play a leading, guiding role to ensure that.

CII Director General Chandrajit Banerjee, said, “CII is happy to acknowledge that medical technology sector is a sunrise sector. Elaborating on the theme of effective governance, Pavan Choudary, chairman, Medical Technology Division, CII said “Classification of medical devices as drugs pose a burden to the process of investment with fiscal policy obstacles and regulatory hurdles. It impacts FDI, technology transfer, local investment, manufacturing, operations, innovation and exports”.

“The Vision Document 2025 highlights the need for a dedicated, separate and globally harmonised regulation for medical devices”, added Himanshu Baid, co-chairman, CII Medical Equipment Division. Rahul Guha, partner and director, Boston Consulting Group (BCG) India remarked that there was lack of investment, lack of regulation, less priority of the government and this was therefore a vicious circle. “The innovations and the licenses is something that unfortunately is not going in tandem with each other,” Guha said.

To build up a roadmap for India to reach its full potential in medical technology, CII and BCG assembled a think tank of 40+ industry participants to brainstorm and determine the key levers required to be able to unlock the true potential of India. BCG held a set of workshops across Mumbai and Delhi to discuss and debate the right focus areas and develop a roadmap to unlock this potential.

Among the key recommendations proposed by the CII-BCG Report are need for a separate regulatory act for medical technology, need for manufacturing incentives (for example tax support, low cost funding to spur investments), single–window clearance to ease the regulatory burden for the industry, creation of ‘National Innovation Policy’ to reward results in innovation, need for world-class manufacturing infrastructure, setting up of collaborative partnerships, investing in Capability Development and Training by setting up Centers of Excellence for medical technology training, global task force to promote India as a manufacturing and R&D hub globally, create industry sponsored programs between local and global industry on joint collaboration projects, industry academia collaboration and to facilitate Curriculum adaptation as well as crosspollination of knowledge between students of Medical Technology and Business Management.

(Ref: http://www.pharmabiz.com/PrintArticle.aspx?aid=83659&sid=1)


Commerce Ministry Brings Export Of Medical Devices, Pharma Machinery Under EEPC

In a strategic move to address major export related concerns of the medical device and pharma machinery sector, the Government recently announced that EEPC INDIA formerly Engineering Export Promotion Council will henceforth handle the export related issues and promotional activities of the industry. It is understood that the government took this decision after lot of deliberation and suggestions from Pharmexcil who has been handling the sector till recently and the stakeholders, simultaneously.

EEPC deals with export promotion of engineering goods, projects and services from India.

The information shared by the ministry of commerce in a meeting with the stakeholder held in Gujarat last week, was well received by the industry as experts feel that finally the exporters of the medical device and pharma machinery industry will get a deserving platform to raise their issues and concerns with the government. This move stems from the fact that there had been a strong consensus within the industry that medical device and machinery industry, an outcome of engineering marvel, mainly comprising of electronic devices need a larger and appropriate forum than Pharmaceutical Export Promotion Council of India (Pharmexcil).

Interestingly, earlier the Council used to handle exports of only those medical devices notified as drugs under the Drugs & Cosmetics Act, whereas it is understood that now EEPC will be handling exports of all the medical devices. Dr P V Appaji Director General (DG)of Pharmexcil informed that it is practical and feasible move, especially since hardly few companies where members of the Pharmexcil, making it more difficult for the Council to represent the industry at the Centre.

According to D L Pandya, an expert from the medical device industry, this move will enable and open up a lot more opportunities for this sector as there are a lot of issues and challenges that the industry is currently grappling with that needs urgent intervention from the government to boost up the exports.

“Though Pharmexcil is a very competent forum, it had very little role to play for the medical device industry. This made us feel left out from the incremental and developmental scope, which will hopefully change now with all the activities being migrated to EEPC. Now that a suitable forum is given to represent our cause as per our demands we hope to see positive change in the business, with adequate focus being rendered to our industry specific issues,” stressed Pandya who is also the chief executive officer, of Medical Plastics Data Service.

He further informed that to get better exposure they have also demanded to government to include even supply chain companies for medical devices and pharma machinery under the ambit of EEPC as they also make an important part of industry.

(Ref: http://www.pharmabiz.com/NewsDetails.aspx?aid=83175&sid=1)

Other News

Archives

Advertisement

 

 


Back | Back To Top | Previous | Next